• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Luna Innovations Incorporated investors: Please contact the Portnoy Law Firm to recover your losses; May 31, 2024 deadline

    5/13/24 7:20:45 PM ET
    $LUNA
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Get the next $LUNA alert in real time by email

    Investors can contact the law firm at no cost to learn more about recovering their losses

    ​LOS ANGELES, May 13, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Luna Innovations Incorporated (NASDAQ:LUNA) investors that a lawsuit was filed on behalf of investors that purchased Luna securities between August 11, 2023 and March 25, 2024 inclusive (the "Class Period").

    Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: [email protected], to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors' options for pursuing claims to recover their losses.

    • The lawsuit alleges that throughout the class period, the defendants neglected to reveal that: (1) Luna Innovations' financial reports from August 10, 2023, to the present contained inaccuracies due to incorrect revenue accounting; (2) consequently, Luna Innovations was required to correct its financial statements previously submitted from August 10, 2023, to November 14, 2023; and (3) Luna Innovations did not have sufficient internal oversight mechanisms in place. The disclosure of these facts led to a decline in Luna Innovations' stock value, resulting in financial losses for investors.

    Please visit our website to review more information and submit your transaction information.

    The Portnoy Law Firm represents investors in pursuing claims caused by corporate wrongdoing. The Firm's founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes.

    Lesley F. Portnoy, Esq.

    Admitted CA and NY Bar

    [email protected]

    310-692-8883

    www.portnoylaw.com

    Attorney Advertising



    Primary Logo

    Get the next $LUNA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $LUNA

    DatePrice TargetRatingAnalyst
    7/28/2023$12.50Buy
    Stifel
    5/22/2023$10.00Buy
    Needham
    3/15/2023$8.00Outperform → Market Perform
    Northland Capital
    5/23/2022$8.00Market Perform → Outperform
    Northland Capital
    More analyst ratings

    $LUNA
    SEC Filings

    See more
    • Luna Innovations Incorporated filed SEC Form 8-K: Results of Operations and Financial Condition, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits

      8-K - LUNA INNOVATIONS INC (0001239819) (Filer)

      1/27/25 10:26:44 AM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form SCHEDULE 13G filed by Luna Innovations Incorporated

      SCHEDULE 13G - LUNA INNOVATIONS INC (0001239819) (Subject)

      1/14/25 1:56:29 PM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Luna Innovations Incorporated filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - LUNA INNOVATIONS INC (0001239819) (Filer)

      1/6/25 8:30:40 AM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $LUNA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Luna Announces Strong Start to 2025 with Substantial Bookings Growth

      Luna Innovations Incorporated (OTC:LUNA) ("Luna" or the "Company"), a global leader in advanced fiber optic-based technology, today announced select preliminary operating and financial metrics for the first quarter ended March 31, 2025, showcasing significant year-over-year bookings growth, continued gross margin expansion, and sustained execution on cost containment initiatives. "We are pleased to report a strong start to 2025, with sharp improvements in bookings, margin performance, and working capital management," said the Company's President, Chief Executive Officer, Kevin Ilcisin. "Our continued focus on operational discipline, customer alignment, and profitable growth is positioning

      5/20/25 8:48:00 AM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Luna Innovations Announces Baker Tilly as New Independent Auditor

      Luna Innovations Incorporated (OTC:LUNA) (the "Company"), a global leader in advanced fiber optic-based technology, is pleased to announce the appointment of Baker Tilly US LLP ("Baker Tilly"), as its independent accounting firm, effective as of March 20, 2025. This follows the previously disclosed resignation of Ernst & Young LLP, as reported in the Company's February 2025 SEC filing. The Audit Committee of the Company's Board of Directors has engaged Baker Tilly to audit the Company's consolidated financial statements for the fiscal years ending December 31, 2023 and 2024. In addition, Baker Tilly will conduct reviews of the Company's unaudited condensed consolidated quarterly financial

      4/2/25 8:52:00 AM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Luna Announces Updates on Operating Metrics and Intent to Deregister Stock

      Luna Innovations Incorporated (OTC:LUNA) (the "Company"), a global leader in advanced fiber optic-based technology, today announces an update on select operating metrics. The Company is also communicating its intent to voluntarily accelerate its delisting from Nasdaq and ultimately deregister its common stock under Section 12(b) and Section 12(g) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), including suspending its reporting obligations under Section 15(d) of the Exchange Act. The accelerated delisting and deregistration process will not adversely affect Luna's ongoing operations or the listing of the Company's common stock on the OTC Experts Market. "Luna star

      1/27/25 10:24:00 AM ET
      $LUNA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care